Related Experiment Video
Updated: Jan 27, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Variable access to antiviral treatment of chronic hepatitis B in Canada: a descriptive study
Stephen E Congly1, Mayur Brahmania2
1University of Calgary Liver Unit (Congly), Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alta.; Division of Gastroenterology, Department of Medicine, and Multi Organ Transplant Unit (Brahmania), London Health Sciences Centre, Western University, London, Ont.
Background:
Antiviral treatment for chronic hepatitis B is costly, which presents challenges for universal drug coverage for the estimated 480 000 people with the disease in Canada. We appraised criteria for reimbursement of chronic hepatitis B antivirals by public drug plans in Canada.
Methods:
In this descriptive study, we reviewed the reimbursement criteria for lamivudine, adefovir, tenofovir, entecavir, telbivudine, pegylated or standard interferon, and emtricitabine-tenofovir in the 10 provinces and the Yukon Territory as well as 3 federal programs: Correctional Services Canada, Veterans' Affairs and the Non-Insured Health Benefits Program. We extracted data from publicly available formularies. The primary outcomes extracted were prescriber details, reimbursement regulations and published list price.
Results:
All public drug insurance plans limit access to antiviral treatment in patients with chronic hepatitis B based on viral characteristics, fibrosis stage and/or specialist approval. Lamivudine use is restricted only in British Columbia and Ontario. Six plans (43%) cover entecavir or tenofovir with no restriction, and 8 plans (57%) cover these agents if patients have advanced fibrosis/cirrhosis. Nine plans (64%) provide coverage of interferon, although 4 of these programs reimburse only nonpegylated interferon, which is not currently recommended for chronic hepatitis B treatment.
Interpretation:
We found substantial variability among jurisdictions in reimbursement criteria for the treatment of chronic hepatitis B in Canada. The findings can inform health policy and support the development and adoption of a national chronic hepatitis B strategy to ensure equitable and timely access to treatment no matter where patients reside in Canada.
More Related Videos
Related Concept Videos
Pleural Disorders: Types and Brief Description
Eulerian and Lagrangian Flow Descriptions
The Eulerian method focuses on fixed points in space where fluid properties, such as velocity, pressure, and temperature, are observed as the fluid moves between these...
Variability: Analysis
The range is a simple measure of variability, indicating the difference between the highest and...
Random Variables
Uppercase letters such as X or Y denote a random variable. Lowercase letters like x or y denote the value of a random variable. If X is a random variable, then X is written in words, and x is given as a number.
For example, let X = the...
Variables Affecting Phosphorescence and Fluorescence
The Antiviral System of Bacteria and Archaea: CRISPR

